An IL-4/IL-13 dual antagonist reduces lung inflammation, airway hyperresponsiveness, and IgE production in mice

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 1, 2013, Pages 37-46

  Kasaian, Marion T ^a   Marquette, Kimberly ^b   Fish, Susan ^a   DeClercq, Charlene ^a   Agostinelli, Rita ^b   Cook, Timothy A ^a   Brennan, Agnes ^a   Lee, Julie ^b   Fitz, Lori ^b   Brooks, Jonathan ^b   Vugmeyster, Yulia ^b   Williams, Cara M M ^b   Lofquist, Alan ^c   Tchistiakova, Lioudmila ^b  

^a Department of Immunoscience ^*  (United States)

^b PFIZER INC   (United States)

^c Emergent Biosolutions   (United States)

Author keywords

Asthma; Bifunctional; Cytokine; Th2

Indexed keywords

ALLERGEN; CHITINASE; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; LAT PROTEIN; NUCLEIC ACID BINDING PROTEIN; OVALBUMIN; SCAFFOLD PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AIRWAY RESISTANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; BINDING AFFINITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; EAR SWELLING; FEMALE; GENE EXPRESSION; GENE FUNCTION; IMMUNOGLOBULIN BLOOD LEVEL; LOEFFLER PNEUMONIA; LUNG FUNCTION; MOUSE; NONHUMAN; PNEUMONIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN TARGETING; RESPIRATORY TRACT ALLERGY; SENSITIZATION; STEADY STATE; SWELLING; TH2 CELL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING SITES; BRONCHIAL HYPERREACTIVITY; CHO CELLS; CRICETINAE; CROSS-LINKING REAGENTS; EAR; FEMALE; HALF-LIFE; IMMUNOGLOBULIN E; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; MOLECULAR CONFORMATION; NEUTRALIZATION TESTS; OVALBUMIN; PNEUMONIA; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; SINGLE-CHAIN ANTIBODIES;

EID: 84883158559     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0500OC     Document Type: Article

References (67)

1. Zurawski SM, Chomarat P, Djossou O, Bidaud C, McKenzie AN, Miossec P, Banchereau J, Zurawski G. The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J Biol Chem 1995;270:13869-13878.
2. Wills-Karp M, Finkelman FD. Untangling the complex web of IL-4-and IL-13-mediated signaling pathways. Sci Signal 2008;1:pe55.
3. Venkayya R, Lam M, Willkom M, Grunig G, Corry DB, Erle DJ. The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells. Am J Respir Cell Mol Biol 2002;26:202-208.
4. Perkins C, Wills-Karp M, Finkelman FD. IL-4 induces IL-13-independent allergic airway inflammation. J Allergy Clin Immunol 2006;118:410-419.
5. Munitz A, Brandt EB, Mingler M, Finkelman FD, Rothenberg ME. Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the Type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci USA 2008;105:7240-7245.
6. Ramalingam TR, Pesce JT, Sheikh F, Cheever AW, Mentink-Kane MM, Wilson MS, Stevens S, Valenzuela DM, Murphy AJ, Yancopoulos GD, et al. Unique functions of the Type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat Immunol 2008;9:25-33.
7. Webb DC, Cai Y, Matthaei KI, Foster PS. Comparative roles of IL-4, IL-13, and IL-4Ralpha in dendritic cell maturation and CD41 Th2 cell function. J Immunol 2007;178:219-227.
8. Rothenberg ME, Wen T, Shik D, Cole ET, Mingler MM, Munitz A. IL-13 receptor alpha1 differentially regulates aeroallergen-induced lung responses. J Immunol 2011;187:4873-4880.
9. McKenzie GJ, Fallon PG, Emson CL, Grencis RK, McKenzie AN. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell Type 2-mediated responses. J Exp Med 1999;189:1565-1572.
10. Fish SC, Donaldson DD, Goldman SJ, Williams CM, Kasaian MT. IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13. J Immunol 2005;174:7716-7724.
11. Tomkinson A, Duez C, Cieslewicz G, Pratt JC, Joetham A, Shanafelt MC, Gundel R, Gelfand EW. A murine IL-4 receptor antagonist that inhibits IL-4-and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J Immunol 2001; 166:5792-5800.
12. Webb DC, McKenzie AN, Koskinen AM, Yang M, Mattes J, Foster PS. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol 2000;165:108-113.
13. Corren J, BusseW,Meltzer EO,Mansfield L, Bensch G, Fahrenholz J,Wenzel SE, Chon Y, Dunn M, Weng HH, et al. A randomized, controlled, Phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181:788-796.
14. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two Phase 2A studies. Lancet 2007;370:1422-1431.
15. Burmeister Getz E, Fisher DM, Fuller R. Human pharmacokinetics/ pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J Clin Pharmacol 2009;49:1025-1036.
16. Chiba Y, Todoroki M, Nishida Y, Tanabe M, Misawa M. A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. Am J Respir Cell Mol Biol 2009;41:516-524.
17. Nagashima S, Hondo T, Nagata H, Ogiyama T, Maeda J, Hoshii H, Kontani T, Kuromitsu S, Ohga K, Orita M, et al. Novel 7H-pyrrolo [2,3-D]pyrimidine derivatives as potent and orally active STAT6 inhibitors. Bioorg Med Chem 2009;17:6926-6936.
18. Perez GM, Cortes JR, Rivas MD, Masa F, Zamorano J. Treatment of cells with N-alpha-tosyl-L-phenylalanine-chloromethyl ketone induces the proteolytic loss of STAT6 transcription factor. Mol Immunol 2008; 45:3896-3901.
19. Siemasko K, Chong AS, Jack HM, Gong H, Williams JW, Finnegan A. Inhibition of Jak3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998;160:1581-1588.
20. Suzuki K, Nakajima H, Ikeda K, Tamachi T, Hiwasa T, Saito Y, Iwamoto I. STAT6-protease but not STAT5-protease is inhibited by an elastase inhibitor ONO-5046. Biochem Biophys Res Commun 2003; 309:768-773.
21. Martin RM, Brady JL, Lew AM. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 1998;212:187-192.
22. Fitz LJ, DeClercq C, Brooks J, Kuang W, Bates B, Demers D, Winkler A, Nocka K, Jiao A, Greco RM, et al. Acidic mammalian chitinase is not a critical target for allergic airway disease. Am J Respir Cell Mol Biol 2012;46:71-79.
23. Finkelman FD, Katona IM, Urban JF Jr., Snapper CM, Ohara J, Paul WE. Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1. Proc Natl Acad Sci USA 1986;83:9675-9678.
24. Zhou J, Pop LM, Ghetie V. Hypercatabolism of IgG in mice with lupuslike syndrome. Lupus 2005;14:458-466.
25. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 1996;89:573-578.
26. Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, He CH, Takyar S, Elias JA. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 2011;73:479-501.
27. Homer RJ, Zhu Z, Cohn L, Lee CG, White WI, Chen S, Elias JA. Differential expression of chitinases identify subsets of murine airway epithelial cells in allergic inflammation. Am J Physiol Lung Cell Mol Physiol 2006;291:L502-L511.
28. Rose MC, Piazza FM, Chen YA, Alimam MZ, Bautista MV, Letwin N, Rajput B. Model systems for investigating mucin gene expression in airway diseases. J Aerosol Med 2000;13:245-261.
29. Zuhdi Alimam M, Piazza FM, Selby DM, Letwin N, Huang L, Rose MC. Muc-5/5ac mucin messenger RNA and protein expression is a marker of goblet cell metaplasia in murine airways. Am J Respir Cell Mol Biol 2000;22:253-260.
30. Seong JK, Koo JS, Lee WJ, Kim HN, Park JY, Song KS, Hong JH, Yoon JH. Upregulation ofMuc8 and downregulation ofMuc5ac by inflammatory mediators in human nasal polyps and cultured nasal epithelium. Acta Otolaryngol 2002;122:401-407.
31. Kasaian MT, Miller DK. IL-13 as a therapeutic target for respiratory disease. Biochem Pharmacol 2008;76:147-155.
32. Yang M, Hogan SP, Henry PJ, Matthaei KI, McKenzie AN, Young IG, Rothenberg ME, Foster PS. Interleukin-13 mediates airways hyperreactivity through the IL-4 receptor-alpha chain and STAT-6 independently of IL-5 and eotaxin. Am J Respir Cell Mol Biol 2001;25:522-530.
33. Kuperman D, Schofield B, Wills-Karp M, Grusby MJ. Signal transducer and activator of transcription factor 6 (STAT6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J ExpMed 1998;187:939-948.
34. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-1098.
35. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, Kell C, May RD, Geba GP, et al. A Phase 2 placebo-controlled study of tralokinumab in moderate-to-severe asthma.Eur Respir J 2013; 41:330-338.
36. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010;19:46-54.
37. Corren J. Cytokine inhibition in severe asthma: current knowledge and future directions. Curr Opin Pulm Med 2011;17:29-33.
38. Steinke JW. Anti-interleukin-4 therapy. Immunol Allergy Clin North Am 2004;24:599-614.
39. Borish L. IL-4 and IL-13 dual antagonism: a promising approach to the dilemma of generating effective asthma biotherapeutics. Am J Respir Crit Care Med 2010;181:769-770.
40. Karras JG, Crosby JR, Guha M, Tung D, Miller DA, Gaarde WA, Geary RS, Monia BP, Gregory SA. Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice. Am J Respir Cell Mol Biol 2007;36:276-285.
41. Hahn C, Teufel M, Herz U, Renz H, Erb KJ, Wohlleben G, Brocker EB, Duschl A, Sebald W, Grunewald SM. Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma. J Allergy Clin Immunol 2003;111:1361-1369.
42. Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012;4:182-197.
43. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126-1136.
44. Teplyakov A, Obmolova G, Carton JM, Gao W, Zhao Y, Gilliland GL. On the domain pairing in chimeric antibodies. Mol Immunol 2010;47: 2422-2426.
45. Mabry R, Lewis KE,Moore M, McKernan PA, Bukowski TR, Bontadelli K, Brender T, Okada S, Lum K, West J, et al. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng Des Sel 2010;23:115-127.
46. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007;25:1290-1297.
47. Sengoku T, Sato S, Sakuma S, Ogawa T, OhkuboY, Goto T. Characterization of ascaris-induced biphasic skin allergic reaction model in mice: possible roles of mast cells in early-phase and CD4-positive T cells in latephase reactions. Pharmacology 2001;63:82-89.
48. Weigmann B, Schwing J, Huber H, Ross R, Mossmann H, Knop J, Reske-Kunz AB. Diminished contact hypersensitivity response in IL-4 deficient mice at a late phase of the elicitation reaction. Scand J Immunol 1997;45:308-314.
49. Togawa M, Kiniwa M, Nagai H. The roles of IL-4, IL-5 and mast cells in the accumulation of eosinophils during allergic cutaneous late phase reaction in mice. Life Sci 2001;69:699-705.
50. Walter DM, McIntire JJ, Berry G, McKenzie AN, Donaldson DD, DeKruyff RH, Umetsu DT. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol 2001;167:4668-4675.
51. McKenzie GJ, Emson CL, Bell SE, Anderson S, Fallon P, Zurawski G, Murray R, Grencis R, McKenzie AN. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 1998;9:423-432.
52. Fallon PG, Emson CL, Smith P, McKenzie AN. IL-13 overexpression predisposes to anaphylaxis following antigen sensitization. J Immunol 2001;166:2712-2716.
53. Emson CL, Bell SE, Jones A, Wisden W, McKenzie AN. Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13. J Exp Med 1998;188:399-404.
54. Muller U, Stenzel W, Kohler G, Werner C, Polte T, Hansen G, Schutze N, Straubinger RK, Blessing M, McKenzie AN, et al. IL-13 induces disease-promoting Type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J Immunol 2007;179:5367-5377.
55. Wang Y, McCusker C. Neonatal exposure with LPS and/or allergen prevents experimental allergic airways disease: development of tolerance using environmental antigens. J Allergy Clin Immunol 2006; 118:143-151.
56. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-2261.
57. Taube C, Duez C, Cui ZH, Takeda K, Rha YH, Park JW, Balhorn A, Donaldson DD, Dakhama A, Gelfand EW. The role of IL-13 in established allergic airway disease. J Immunol 2002;169:6482-6489.
58. Nagai H, Maeda Y, Tanaka H. The effect of anti-IL-4 monoclonal antibody, rapamycin and interferon-gamma on airway hyperreactivity to acetylcholine in mice. Clin Exp Allergy 1997;27:218-224.
59. Thyphronitis G, Katona IM, Gause WC, Finkelman FD. Germline and productive C epsilon gene expression during in vivo IgE responses. J Immunol 1993;151:4128-4136.
60. Finkelman FD, Katona IM, Urban JF Jr., Holmes J, Ohara J, Tung AS, Sample JV, Paul WE. IL-4 is required to generate and sustain in vivo IgE responses. J Immunol 1988;141:2335-2341.
61. Sher A, Coffman RL, Hieny S, Cheever AW. Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni in the mouse. J Immunol 1990;145:3911-3916.
62. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998;282:2261-2263.
63. Elias JA, Homer RJ, Hamid Q, Lee CG. Chitinases and chitinase-like proteins in T(h)2 inflammation and asthma. J Allergy Clin Immunol 2005;116:497-500.
64. Berry LM, Adams R, Airey M, Bracher MG, Bourne T, Carrington B, Cross AS, Davies GC, Finney HM, Foulkes R, et al. In vitro and in vivo characterisation of anti-murine IL-13 antibodies recognising distinct functional epitopes. Int Immunopharmacol 2009;9:201-206.
65. Hajoui O, Zheng H, Guay J, Letuve S, Fawaz LM, Mazer BD. Regulation of IL-13 receptor alpha 1 expression and signaling on human tonsillar B-lymphocyte subsets. J Allergy Clin Immunol 2007;120:1425-1432.
66. Hart PH, Bonder CS, Balogh J, Dickensheets HL, Donnelly RP, Finlay-Jones JJ. Differential responses of human monocytes and macrophages to IL-4 and IL-13. J Leukoc Biol 1999;66:575-578.
67. David M, Bertoglio J, Pierre J. TNF-alpha potentiates IL-4/IL-13-induced IL-13Ralpha2 expression. Ann N Y Acad Sci 2002;973:207-209.